Calderasib clinical trials
Also written MK-1084.
How each study uses calderasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the calderasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses calderasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07431827Written as Calderasib
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06345729Written as Calderasib
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Calderasib
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07190248Written as Calderasib
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07554339Written as Calderasib
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07252739Written as MK-1084
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07209111Written as Calderasib
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT05067283Written as Calderasib
- A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)CompletedPhase 1Merck Sharp & Dohme LLCNCT07219550Written as Calderasib
- A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)CompletedPhase 1Merck Sharp & Dohme LLCNCT06687759Written as [14C]Calderasib
- A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT06814119Written as Calderasib
- A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)CompletedPhase 1Merck Sharp & Dohme LLCNCT06619314Written as Calderasib
Given beside what is tested · 5 — calderasib is usual care or a partner of the new treatment
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07286149Written as MK-1084
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)Active, not recruitingPhase 1Merck Sharp & Dohme LLCNCT05853367Written as MK-1084
- A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)CompletedPhase 1Merck Sharp & Dohme LLCNCT07222098Written as Calderasib
- A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)CompletedPhase 1Merck Sharp & Dohme LLCNCT06719557Written as Calderasib
- A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06575933Written as Calderasib
Codes
What other systems call calderasib · ClinicalTrials.gg INT018612
- UNII (FDA) YQF4ART47CCALDERASIBConfirmed FDA, Wikidata
- Wikidata Q140528731calderasibConfirmed FDA, Wikidata
- NCI Thesaurus C185288CalderasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YQF4ART47C | CALDERASIB | Confirmed FDA, Wikidata |
| Wikidata | Q140528731 | calderasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C185288 | Calderasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.